Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Management characterizes the current phase as an 'inflection point' where the focus shifts from building AI models to translating them into tangible clinical evidence and measurable impact.